HUE046752T2 - Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával - Google Patents

Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával

Info

Publication number
HUE046752T2
HUE046752T2 HUE14714815A HUE14714815A HUE046752T2 HU E046752 T2 HUE046752 T2 HU E046752T2 HU E14714815 A HUE14714815 A HU E14714815A HU E14714815 A HUE14714815 A HU E14714815A HU E046752 T2 HUE046752 T2 HU E046752T2
Authority
HU
Hungary
Prior art keywords
immunoglobulin
treatment
nervous system
central nervous
intranasal administration
Prior art date
Application number
HUE14714815A
Other languages
English (en)
Hungarian (hu)
Inventor
William Frey
Leah Ranae Hanson
Sharon Pokropinski
Francisco Rausa
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of HUE046752T2 publication Critical patent/HUE046752T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
HUE14714815A 2013-02-26 2014-02-25 Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával HUE046752T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US201361862814P 2013-08-06 2013-08-06

Publications (1)

Publication Number Publication Date
HUE046752T2 true HUE046752T2 (hu) 2020-03-30

Family

ID=50424697

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14714815A HUE046752T2 (hu) 2013-02-26 2014-02-25 Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával

Country Status (13)

Country Link
US (5) US9556260B2 (enExample)
EP (2) EP3597220A1 (enExample)
JP (1) JP6379113B2 (enExample)
AU (2) AU2014223679B2 (enExample)
DK (1) DK2961426T3 (enExample)
ES (1) ES2759226T3 (enExample)
HR (1) HRP20192111T1 (enExample)
HU (1) HUE046752T2 (enExample)
LT (1) LT2961426T (enExample)
PL (1) PL2961426T3 (enExample)
PT (1) PT2961426T (enExample)
SI (1) SI2961426T1 (enExample)
WO (1) WO2014134070A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
EP3129013A1 (en) * 2014-04-10 2017-02-15 Crowley, Patrick Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
WO2020263484A1 (en) * 2019-06-28 2020-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
JP2022544414A (ja) * 2019-08-13 2022-10-18 アルティミューン インコーポレーティッド 治療剤の有効性及びその投与の経路
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
KR100390480B1 (ko) 1995-01-23 2003-10-04 디렉트-할러 아/에스 흡입기
KR100692422B1 (ko) 1999-03-03 2007-03-09 옵티노즈 에이에스 코 내부로 물질을 전달하는 장치
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
MXPA04003156A (es) 2001-10-04 2005-01-25 Protein Therapeutics Inc El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
CN101184499B (zh) 2005-02-23 2012-03-28 阿尔扎公司 活性剂向中枢神经系统的鼻内施用
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
PT1981540E (pt) 2006-01-30 2013-05-07 Grifols Therapeutics Inc Método de tratamento e profilaxia de doenças relacionadas com a deposição de amilóides utilizando igm
CN101410134A (zh) * 2006-02-15 2009-04-15 台拉维夫大学拉莫特 展示蛋白质a作为向脑部递送的抗体和免疫复合物的结合剂的丝状噬菌体
WO2008154337A1 (en) 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
EP2257804B1 (en) * 2008-02-29 2013-12-11 Baxter International Inc. Anti-amyloid activity of intravenous immunoglobulin (ivig) in vitro
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
TR201903403T4 (tr) * 2010-02-04 2019-04-22 Csl Behring Ag İmmünoglobulin preparatı.
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
ES2759226T3 (es) 2020-05-08
US20190055307A1 (en) 2019-02-21
US20210101967A1 (en) 2021-04-08
LT2961426T (lt) 2019-12-27
US12503501B2 (en) 2025-12-23
US20170044244A1 (en) 2017-02-16
US20140242067A1 (en) 2014-08-28
AU2014223679B2 (en) 2018-11-29
US20240117025A1 (en) 2024-04-11
AU2014223679A1 (en) 2015-09-24
US9556260B2 (en) 2017-01-31
HRP20192111T1 (hr) 2020-03-20
AU2018260883A1 (en) 2018-11-29
JP6379113B2 (ja) 2018-08-22
EP3597220A1 (en) 2020-01-22
PT2961426T (pt) 2019-12-09
DK2961426T3 (da) 2019-12-02
EP2961426A1 (en) 2016-01-06
EP2961426B1 (en) 2019-10-30
SI2961426T1 (sl) 2020-01-31
AU2018260883B2 (en) 2020-08-06
US10144776B2 (en) 2018-12-04
WO2014134070A1 (en) 2014-09-04
JP2016512490A (ja) 2016-04-28
US11851481B2 (en) 2023-12-26
PL2961426T3 (pl) 2020-02-28

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL271085A (en) Bacteria for the treatment of disorders
HUE046752T2 (hu) Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával
IL257978B (en) Use of pasteurized akkermansia for treating metabolic disorders
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
DK3328880T3 (da) Terapeutiske midler
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
DK3311824T3 (da) Cd47 målrettede terapier til behandlingen af infektionssygdomme
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
LT2994160T (lt) Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
PT3626270T (pt) Tratamento de doenças cardiovasculares
DK3065818T3 (da) Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
EP3356516A4 (en) CULTIVATION OF HUMAN NOROVIRES
IL257764B (en) Methods for treatment of diseases
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme